Aurobindo Pharma Ltd
NSE:AUROPHARMA
Aurobindo Pharma Ltd
NSE:AUROPHARMA
Price:
1 229.1
INR
0.29%
Market Closed
Market Cap:
₹713.9B
Relative Value
The Relative Value of one
AUROPHARMA
stock under the Base Case scenario is
1 417.96
INR.
Compared to the current market price of 1 229.1 INR,
Aurobindo Pharma Ltd
is
Undervalued by 13%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
AUROPHARMA
Relative Value
Base Case
1 417.96
INR
Undervaluation 13%
Multiples Across Competitors
AUROPHARMA Competitors Multiples
Aurobindo Pharma Ltd Competitors
Aurobindo Pharma Ltd Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| IN |
|
Aurobindo Pharma Ltd
NSE:AUROPHARMA
|
715.7B INR | 2.1 | 20.3 | 9.4 | 12.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
924.2B USD | 14.2 | 44.8 | 30.2 | 32.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
571.8B USD | 6.1 | 21.4 | 14.8 | 18.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
271B CHF | 4.4 | 21 | 12.4 | 13.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
236.2B CHF | 5.4 | 21.8 | 13.5 | 17.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.8B GBP | 5.1 | 29.5 | 16.3 | 23 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
283.3B USD | 4.4 | 15.5 | 9.7 | 11.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.7 | 8 | 9.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.5B USD | 2.4 | 19.4 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
120.4B USD | 2.5 | 17.1 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
